Does ibrutinib/ibrutinib need to be taken for life? What should patients pay attention to?

Ibrutinib/Ibrutinib (Ibrutinib) is an irreversible Bruton tyrosine kinase (BTK) inhibitor that is widely used in the treatment of a variety of B cell-related hematological malignancies. Including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia (WM) and chronic graft-versus-host disease (cGVHD), etc. Due to its mechanism characteristics, ibrutinib does not set a fixed course of treatment like chemotherapy, but emphasizes "continuous treatment", that is, long-term maintenance of medication until the disease does not progress significantly or intolerable side effects occur. The design of this therapeutic strategy is based on the need for sustained inhibition of BTK signaling to maximize control of malignant B cell growth and survival.

In clinical practice, many patients do need to use ibrutinib for a long time or even lifelong, especially in chronic progressive diseases such asCLL and WM. Studies have shown that intermittent use or arbitrary discontinuation of drugs can easily lead to rapid relapse of the disease and even the emergence of drug resistance that is more difficult to control. The main goal of ibrutinib is not to completely eliminate cancer cells, but to keep the disease under control through long-term suppression. Because of this, "whether to take medication for life" depends more on individual disease control, the acceptability of adverse reactions, and the patient's overall tolerance.

However, while taking ibrutinib for a long time, patients must pay close attention to possible toxic reactions, such as bleeding tendencies, increased risk of infection, irregular heartbeat (especially atrial fibrillation), skin rash, and gastrointestinal discomfort. Once serious adverse reactions occur, doctors usually consider temporarily discontinuing the drug, reducing the dose, or changing the drug. Some patients develop drug resistance after a period of treatment. At this time, they may need to switch to second- or third-generation BTK inhibitors, or consider combination regimens.

Reference materials:https://www.imbruvica.com/